NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Shares Shorted: Short Interest Down 49.8% in September

by · The Cerbat Gem

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW – Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 893 shares, a decline of 49.8% from the September 15th total of 1,779 shares. Based on an average daily volume of 2,775 shares, the short-interest ratio is presently 0.3 days.

NeuroSense Therapeutics Stock Up 25.2%

NRSNW traded up $0.00 on Thursday, hitting $0.01. The company’s stock had a trading volume of 10,030 shares, compared to its average volume of 2,602. The company’s 50 day simple moving average is $0.06 and its 200-day simple moving average is $0.11. NeuroSense Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.54.

About NeuroSense Therapeutics

(Get Free Report)

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. The company focuses on conditions with significant unmet medical needs, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.

Its lead product candidate, PrimeC, is an investigational combination therapy designed to address multiple disease mechanisms associated with ALS. PrimeC combines ciprofloxacin and celecoxib in a proprietary formulation and has been evaluated in clinical studies involving patients with ALS.

Further Reading